Research the Value of the Type B Natriuretic Peptide (Nt-ProBnp) In the Treatment of Heart Failure in Children

Vinh NA\textsuperscript{1*}, Hong TTM\textsuperscript{1}, Ngo Anh Vinh
Emergency Department of National Children's Hospital, Viet Nam

Abstract: Measurement of the type B Natriuretic peptide (NT-ProBNP) has become a potent diagnostic aid as a means of identifying patients with heart failure. Therefore, we conducted a study to assess the effects of NT-proBNP-guided therapy of children with heart failure.

Objective: To study the value of the type B Natriuretic peptide (NT-proBNP) in treatment of heart failure in children.

Study method: A prospective case-control study was carried out. Study patients: 100 children were diagnosed with heart failure and they were also classified into different degrees of heart failure according to modified Ross Heart Failure Classification. The control group had 100 patients without cardiovascular disease. Quantitative serum NT-proBNP concentrations and cardiac ultrasound data were analyzed before and after treatment and compared between the treatment group and the control group.

Results: NT-proBNP concentration in a disease group (HF) was 1125.26 ± 1823.40 pg/ml. The concentration level in the control group was 26.74 ± 38.79 pg/ml. The difference between the two groups is statistically significant (p < 0.01). NT-ProBNP concentrations decrease with the state to improve the level of heart failure after treatment.

Conclusion: NT-proBNP is valuable to assess the outcomes of treatment for children with heart failure.

Keyword: NT-ProBNP, heart failure, children

I. Introduction

Heart failure is a common disease in children which causes many serious complications, even death, without early diagnosis and on-time treatment. Diagnosis of heart failure relies on clinical symptoms in children but clinical signs are often difficult to diagnose. Currently, NT-proBNP quantitative serum has been widely adopted and is useful in diagnosing heart failure in countries around the world. However, the treatment and prognosis of heart failure in children in Vietnam was very difficult. To assess the outcomes of treatment for children with heart failure, we proceed with the targeted theme: "A study of the role of Natriuretic type B peptide (NT-proBNP) serum in the treatment for children with heart failure".

II. Patients and Methods

1. Patients: A treatment group of 100 pediatric patients with heart failure are diagnosed and classified according to the modified Ross Heart Failure Classification, and a control group of 100 children without cardiovascular disease of the same age and sex as the sick children at the National Children's Hospital from April 2014 to June 2016. Quantitative NT-proBNP serum concentrations and echocardiographic parameters of the study group were assessed before and after treatment and compared to controls.

2. Study method: A prospective case-control study was carried out.

III. Result

1. General characteristics of the study group

1.1. Sex:

Graph 1. Distribution of patients by sex

Graph 1. Distribution of patients by sex
1.2. Age:

Comment:
- Ages disease encountered most 1 months - 5 years old.
- Average age: 45,32 ± 26,37 months

2. The clinical symptoms of heart failure (before - after treatment)

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Before</th>
<th>After</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tachypnea</td>
<td>90</td>
<td>21</td>
<td>&lt;0,05</td>
</tr>
<tr>
<td>Tachycardia</td>
<td>87</td>
<td>19</td>
<td>&lt;0,05</td>
</tr>
<tr>
<td>Hepatomegaly</td>
<td>48</td>
<td>18</td>
<td>&lt;0,05</td>
</tr>
<tr>
<td>Sweating</td>
<td>72</td>
<td>23</td>
<td>&lt;0,05</td>
</tr>
<tr>
<td>Edema</td>
<td>19</td>
<td>7</td>
<td>&lt;0,05</td>
</tr>
</tbody>
</table>

Comment:
The clinical symptoms after treatment have reduced with statistically significant, (p<0.01).

3. The echocardiographic parameters in study group

<table>
<thead>
<tr>
<th>Echocardiographic Parameter</th>
<th>Before</th>
<th>After</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>EF ejection fraction (%)</td>
<td>34,2 ± 2,43%</td>
<td>43 ± 4,78%</td>
<td>&lt;0,05</td>
</tr>
<tr>
<td>Index Bd contractile muscle fibers (%)</td>
<td>48,5 ± 5,61%</td>
<td>54 ± 7,32%</td>
<td>&lt;0,05</td>
</tr>
<tr>
<td>Pulmonary artery pressure systolic (mmHg)</td>
<td>36,32±12,34</td>
<td>25,27 ± 18,45</td>
<td>&lt;0,05</td>
</tr>
</tbody>
</table>

Comment:
Echocardiographic parameters change after treatment with statistically significant, P<0,05.

4. NT-proBNP values in heart failure:

4.1. NT-ProBNP concentration before and after treatment

<table>
<thead>
<tr>
<th>NT- BNP (pg/ml)</th>
<th>Control (n = 100)</th>
<th>Heart failure (n=100)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before</td>
<td>After</td>
<td></td>
</tr>
<tr>
<td></td>
<td>X ± SD</td>
<td>X ± SD</td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>26,74 ± 38,79</td>
<td>1268,26± 1823,40</td>
<td></td>
</tr>
<tr>
<td>Heart Failure</td>
<td>308,89±27,40</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\[ ^{1,2} \text{compare NT-proBNP concentrations between groups of patients before treatment and control group (p<0,001)} \]
IV. Discussion

1. The clinical symptoms of heart failure

When evaluating the results of treatment, the major clinical symptoms of heart failure significantly reduced after treatment with \( p < 0.01 \).

The common symptoms in the heart failure group is the tachypnea and tachycardia, this is the classic symptoms of heart failure. These symptoms have improved after treatment.

2. The echocardiographic parameters in study group

An echocardiogram is an important method to assess cardiac function. The main parameters of ultrasound in the evaluation of cardiac function is EF (left ventricular ejection fraction),%D (left ventricular contractility index), pulmonary systolic arterial pressure. When evaluating these parameters to determine the function of the heart change in children with heart failure in the study, the results showed that the EF and%D parameters in HF group after treatment increased more before treatment (\( p < 0.05 \)). This proves that children with heart failure after treatment is improve. Besides evaluating pulmonary systolic artery pressure between the two groups, the results showed that parameters in the heart failure group before treatment were higher than after treatment. It also showed the group of heart failure right ventricular function after treatment was improve. (Table 3)

This result is consistent with results from a study by YM Law when studied in children [4].

3. NT-proBNP concentration in heart failure group:

When comparing NT-proBNP level between two groups of treatment and control, this parameters in before treatment group higher (1823.40 ± 1125.26pg/ml) control group (26.74 ± 38.79 pg/ml), the difference is significant with \( p < 0.001 \). NT-proBNP level after treatment groups (308.89±27.40) were also higher after the control group, \( p < 0.05 \). When compare before and after heart failure treatment groups, NT-proBNP level before treatment higher (1823.40 ± 1125.26pg/ml)after treatment (308.89±27.40pg/ml) with \( p < 0.05 \). (Table 4.1).This suggests that NT-proBNP level increased in heart failure and this parameter have diagnostic value in children with heart failure. This result is consistent with a study by Thang Pham and colleagues on the research parameters in heart failure in adults [1].

4. The degree of heart failure after treatment

- The degree of heart failure after treatment has decreased when compared before treatment. Classified according to the modified Ross Heart Failure Classification, Level I: control group (without heart failure), Level II (mild heart failure), Level III (medium HF), level IV (severe HF).

Before treatment there were 31 patients with degree IV heart failure (the most serious), but after the treatment there were only 19. Besides the patients with other degrees of heart failure were also reduce after treatment. The study results also showed that all 22 patients following heart failure treatment (Before treatment, 100 patients with heart failure, after treatment for 78 patients with heart failure). (Table 4.2). This result is consistent with a study by John Gand colleagues on the research for treatment in heart failure [4].

- NT-pro BNP increased with the severity of heart failure. However, NT-pro BNP concentration between the degree of heart failure was markedly different and increased with the severity of heart failure from level I to level IV. These parameters increases with the degree of heart failure in clinical practice and the difference between the degree of heart failure is statistically significant (Table 4.2). This proves that with increasing levels of heart failure, NT-proBNP concentrations are higher. Therefore
Reseatch the value of The Type B Natriuretic Peptide (NT-ProBNP) In The Treatment Of Heart Failure...

NT-proBNP is a marker to assess heart failure severity in children, and this is an important role in assessing progress and prognosis in heart failure. So NT-proBNP indicator can help clinicians evaluate the effectiveness of treatment.

V. Conclusion
- NT-proBNP concentration of children with heart failure is higher than children without heart failure.
- NT-proBNP levels increased with the severity levels of heart failure in clinical practice.
- NT-proBNP concentrations are valuable parameters in following up treatment and prognosis of heart failure in children.

References
[1]. Pham Thang, Ta Mạnh Cường, Phan Thanh Nhung (2010), “Study B-type natriuretic concentrations of plasma peptide of patients with chronic heart failure”, Vietnam Medicine, No 1 April 2010, p 51-56.